Introduction to Small Sample Clinical Trials
According to the notification issued by the Pharmaceuticals and Medical Devices Agency (PMDA) on March 19, 2026, the agency published an Early Consideration document outlining key points for planning and conducting clinical trials with limited sample sizes.
While randomized controlled trials (RCTs) remain the gold standard for demonstrating efficacy and safety, PMDA recognizes that in certain situations—such as rare diseases or recruitment challenges—it may be difficult to conduct adequately powered trials within a reasonable timeframe. In such cases, sponsors are expected to design scientifically robust small-sample clinical trials that maximize interpretability.
Definition and Regulatory Context
Small-sample clinical trials are studies that aim to provide key evidence on efficacy and safety but are conducted with fewer participants than required for sufficient statistical power in conventional RCTs. These may include:
The acceptability of such trials depends on multiple factors, including disease characteristics, drug properties, and the overall development program. Early consultation with PMDA is strongly recommended.
Basic Planning Principles
A critical first step is assessing feasibility, including:
Based on these factors, sponsors should evaluate whether:
For single-arm trials, comparisons may be made against external controls or predefined clinical thresholds derived from historical data or registries. However, biases (e.g., lack of blinding) must be carefully addressed.
Key Design and Statistical Considerations
Selection of Endpoints
Primary endpoints should be clinically meaningful and directly linked to study objectives. When traditional endpoints lack sufficient power, surrogate endpoints or biomarkers may be considered, provided their clinical relevance can be justified.
Use of Longitudinal Data
Repeated measurements over time can increase the amount of information obtained from each participant, improving efficiency in small populations.
Adjustment for Covariates
Incorporating prognostic factors through stratification or adjusted analyses may improve statistical power, although feasibility depends on sample size.
Significance Level Adjustment
In some cases, a higher significance level (e.g., 10%) may be considered. However, when evidence relies heavily on a single trial, maintaining the conventional 5% level is generally recommended.
Innovative Trial Designs
These approaches may enhance efficiency but require careful justification and prior discussion with PMDA.
Regulatory Communication and Justification
Sponsors must clearly explain:
If alternative designs (e.g., single-arm trials) are used, justification of external controls or thresholds is essential. Comparative evaluation of multiple design options is also encouraged.
Conclusion
PMDA’s Early Consideration on small sample clinical trials provides important guidance for developing drugs in settings where conventional RCTs are impractical. By emphasizing scientific rigor, innovative methodologies, and early regulatory engagement, the guidance aims to facilitate drug development, particularly in rare diseases and other challenging contexts—while maintaining the reliability of evidence for regulatory decision-making.
Reference